Idronoxil

Drug Profile

Idronoxil

Alternative Names: Dehydroequol; NV 06; Phenoxodiol; PXD

Latest Information Update: 21 Apr 2015

Price : $50

At a glance

  • Originator Novogen
  • Developer MEI Pharma
  • Class Antineoplastics; Hormones; Isoflavones; Small molecules
  • Mechanism of Action Caspase stimulants; NADH oxidase inhibitors; Proto oncogene protein c-akt inhibitors; X-linked inhibitor of apoptosis protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute lymphoblastic leukaemia; Autoimmune disorders; Benign prostatic hyperplasia; Fallopian tube cancer; Leukaemia; Ovarian cancer; Prostate cancer; Renal cancer; Skin cancer; Transplant rejection

Most Recent Events

  • 28 Jun 2012 Marshall Edwards is now called MEI Pharma
  • 01 Feb 2012 Marshall Edwards completes the OVATURE phase III trial in Ovarian cancer in the USA (NCT00382811)
  • 21 Mar 2011 Efficacy data from a phase II trial in Ovarian cancer (Combination therapy with cisplatin) released by Marshall Edwards
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top